Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Insmed ( (INSM) ).
On February 6, 2025, Insmed announced that the FDA accepted its New Drug Application for brensocatib, a potential first-in-class treatment for non-cystic fibrosis bronchiectasis, with a target action date set for August 12, 2025. If approved, brensocatib would be the first treatment for bronchiectasis and the first dipeptidyl peptidase 1 inhibitor, reflecting a significant advancement in treating neutrophil-mediated diseases, potentially impacting the market and offering new hope to patients without existing treatment options.
More about Insmed
Insmed Incorporated is a global biopharmaceutical company focused on developing transformative therapies for serious diseases, particularly in the pulmonary and inflammatory sectors. The company is known for its portfolio of approved and investigational medicines and is recognized as a leading employer in the biopharmaceutical industry.
YTD Price Performance: 16.43%
Average Trading Volume: 1,796,165
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $14.57B
Learn more about INSM stock on TipRanks’ Stock Analysis page.
